BRD9 Degraders Targeting BAF Complex Disorders

The patent applies parameter changes by modifying the chemical structure of compounds to create degraders with specific molecular characteristics. The compounds contain a degradation moiety (B) linked to a bromodomain-containing ligand (A) via a linker (L), where specific structural parameters of B and L determine the compound's ability to target and degrade BRD9. This structural parameter optimization enables effective BRD9 degradation while maintaining therapeutic reliability.

The patent employs composite materials by combining multiple functional moieties into a single compound structure. The compound comprises a degradation moiety (B) that recruits ubiquitin ligases, a linker (L) that connects the moieties, and a bromodomain-containing ligand (A) that binds to BRD9. This composite structure enables the compound to simultaneously perform multiple functions: binding to BRD9, recruiting degradation machinery, and facilitating protein degradation, thereby overcoming the limitations of current single-function treatments.

The patent applies segmentation by dividing the compound into distinct functional segments: a degradation moiety (B), a linker (L), and a bromodomain-containing ligand (A). This segmentation allows each component to perform its specific function independently while working together as a unified degrader. The modular structure facilitates rational drug design and optimization without requiring complete redesign of the entire molecule.

The patent uses the linker (L) as an intermediary component that connects the degradation moiety (B) and the bromodomain-containing ligand (A). The linker serves as a mediator that enables proper spatial arrangement and interaction between the two functional moieties. By optimizing linker properties such as length, flexibility, and chemical composition, the patent achieves effective BRD9 degradation while managing molecular complexity through the use of this intermediary element.